CRH PLC

CRH remains in a Stage 4 decline with a clear Lower Highs & Lower Lows downtrend and bearish EMA alignment. Price is near its 52-week low and below major EMAs, with momentum indicators not signaling a reversal. Short-term timing is neutral, suggesting deferment of sell execution. Preferred approach is to trim into the nearby EMA and resistance cluster rather than initiate fresh sell positions.

• ↑Q2 revenues climbed 6% YoY to $10.8B; 2026 adjusted EBITDA guide at $8.1–$8.5B.
• ↑Acquisitions including $8.5B Arcosa deal and $1.4B other, driving capacity and synergy gains.
• ↓Residential new-build market shows no recovery into 2026, dragging on volume growth.